Richard Pulik - 23 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: CFO
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik
Issuer symbol: ROIV
Transactions as of: 23 Dec 2025
Net transactions value: -$8,121,307
Form type: 4
Filing time: 29 Dec 2025, 21:00:21 UTC
Previous filing: 23 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pulik Richard	CFO	C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM	By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik	29 Dec 2025	0001885841

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$1,001,000	+260,000	+67%	$3.85	646,144	23 Dec 2025	Direct
transaction	ROIV	Common Shares	Sale	$5,837,000	-260,000	-40%	$22.45	386,144	23 Dec 2025	Direct	F1, F2
transaction	ROIV	Common Shares	Sale	$3,285,307	-146,731	-38%	$22.39	239,413	23 Dec 2025	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-260,000	-26%	$0.000000	740,000	23 Dec 2025	Common Stock	260,000	$3.85	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2	These Common Shares were sold in multiple transactions at prices ranging from $22.37 to $22.51, inclusive.
F3	These Common Shares were sold in multiple transactions at prices ranging from $22.28 to $22.54, inclusive.
F4	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).